Ratings Nanexa AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:50 2024-04-26 am EDT			5-day change	1st Jan Change
0.606 ^SEK	-5.31%		-8.46%	-50.73%

Apr. 16	Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	CI
Mar. 08	Transcript : Nanexa AB - Special Call

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Thanks to a sound financial situation, the firm has significant leeway for investment.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The stock, which is currently worth 2024 to 0.23 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

The company has insufficient levels of profitability.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The group usually releases earnings worse than estimated.

	1st Jan change	Capi.	ESG Refinitiv
NANEXA AB	-50.73%	7.5M	-
SEDANA MEDICAL AB	-10.84%	187M	C-
CROSSJECT	-59.36%	82M	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality